Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
Naturally Occurring Peptides and Proteins and Related Drugs
share announcement

Naturally Occurring Peptides and Proteins and Related Drugs

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 10387

Special Issue Editor

Prof. Dr. Predrag Sikirić

E-Mail Website
Guest Editor
Department of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Interests: gastrointestinal tract; cytoprotection; blood vessels; stable gastric pentadecapeptide BPC 157
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The purpose of this Special Issue is to illustrate the further importance of naturally occurring peptides and proteins and related drugs as leads for drug discovery and development. However, there is still a considerable gap between the acknowledged theory, their theoretical significance and practice, and practical implementation in the suited therapy. Therefore, sought-after papers should focus on these advantages being implemented in practice and novel approaches that will be used in the long term. These could include a large variety of important problems and disturbances that remain to be resolved. New vistas, naturally occurring peptides and related drugs as breakthroughs and novel insights could occupy many empty areas in pharmacotherapy and resolve many of currently insurmountable issues.  Hopefully, these will be taken as fully improved therapies in the near future.

Prof. Dr. Predrag Sikirić
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • naturally occurring peptides
  • proteins
  • drug

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 769 KiB  
Article
In Silico Identification of Peanut Peptides Suitable for Allergy Immunotherapy in HLA-DRB1*03:01-Restricted Patients
by Irini Doytchinova, Mariyana Atanasova, Stanislav Sotirov and Ivan Dimitrov
Pharmaceuticals 2024, 17(8), 1097; https://doi.org/10.3390/ph17081097 - 21 Aug 2024
Viewed by 1320
Abstract
Peanut allergy, a prevalent and potentially severe condition affecting millions worldwide, has been linked to specific human leukocyte antigens (HLAs), suggesting increased susceptibility. Employing an immunoinformatic strategy, we developed a “logo model” based on amino acid frequencies in the peptide binding core and [...] Read more.
Peanut allergy, a prevalent and potentially severe condition affecting millions worldwide, has been linked to specific human leukocyte antigens (HLAs), suggesting increased susceptibility. Employing an immunoinformatic strategy, we developed a “logo model” based on amino acid frequencies in the peptide binding core and used it to predict peptides originating from 28 known peanut allergens binding to HLA-DRB1*03:01, one of the susceptibility alleles. These peptides hold promise for immunotherapy in HLA-DRB1*03:01 carriers, offering reduced allergenicity compared to whole proteins. By targeting essential epitopes, immunotherapy can modulate immune responses with minimal risk of severe reactions. This precise approach could induce immune tolerance with fewer adverse effects, presenting a safer and more effective treatment for peanut allergy and other allergic conditions. Full article
(This article belongs to the Special Issue Naturally Occurring Peptides and Proteins and Related Drugs)
►▼ Show Figures

Figure 1

Review

Jump to: Research

30 pages, 4678 KiB  
Review
Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria
by Helal F. Hetta, Nizar Sirag, Shumukh M. Alsharif, Ahmad A. Alharbi, Tala T. Alkindy, Alanoud Alkhamali, Abdullah S. Albalawi, Yasmin N. Ramadan, Zainab I. Rashed and Fawaz E. Alanazi
Pharmaceuticals 2024, 17(11), 1555; https://doi.org/10.3390/ph17111555 - 20 Nov 2024
Cited by 7 | Viewed by 5421
Abstract
The rapid progress of antibiotic resistance among bacteria has prompted serious medical concerns regarding how to manage multidrug-resistant (MDR) bacterial infections. One emerging strategy to combat antibiotic resistance is the use of antimicrobial peptides (AMPs), which are amino acid chains that act as [...] Read more.
The rapid progress of antibiotic resistance among bacteria has prompted serious medical concerns regarding how to manage multidrug-resistant (MDR) bacterial infections. One emerging strategy to combat antibiotic resistance is the use of antimicrobial peptides (AMPs), which are amino acid chains that act as broad-spectrum antimicrobial molecules and are essential parts of the innate immune system in mammals, fungi, and plants. AMPs have unique antibacterial mechanisms that offer benefits over conventional antibiotics in combating drug-resistant bacterial infections. Currently, scientists have conducted multiple studies on AMPs for combating drug-resistant bacterial infections and found that AMPs are a promising alternative to conventional antibiotics. On the other hand, bacteria can develop several tactics to resist and bypass the effect of AMPs. Therefore, it is like a battle between the bacterial community and the AMPs, but who will win? This review provides thorough insights into the development of antibiotic resistance as well as detailed information about AMPs in terms of their history and classification. Furthermore, it addresses the unique antibacterial mechanisms of action of AMPs, how bacteria resist these mechanisms, and how to ensure AMPs win this battle. Finally, it provides updated information about FDA-approved AMPs and those that were still in clinical trials. This review provides vital information for researchers for the development and therapeutic application of novel AMPs for drug-resistant bacterial infections. Full article
(This article belongs to the Special Issue Naturally Occurring Peptides and Proteins and Related Drugs)
►▼ Show Figures

Figure 1

13 pages, 2261 KiB  
Review
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats—A Review
by Salem Bajramagic, Marko Sever, Fran Rasic, Mario Staresinic, Anita Skrtic, Lidija Beketic Oreskovic, Ivana Oreskovic, Sanja Strbe, Svjetlana Loga Zec, Josip Hrabar, Luka Coric, Matea Prenc, Vladimir Blagaic, Klara Brcic, Alenka Boban Blagaic, Sven Seiwerth and Predrag Sikiric
Pharmaceuticals 2024, 17(8), 1081; https://doi.org/10.3390/ph17081081 - 17 Aug 2024
Cited by 1 | Viewed by 3128
Abstract
By introducing the healing of many distinctive anastomoses by BPC 157 therapy, this review practically deals with the concept of the resection and reconnection of the hollow parts of the gastrointestinal tract as one of the cornerstones of visceral surgery. In principle, the [...] Read more.
By introducing the healing of many distinctive anastomoses by BPC 157 therapy, this review practically deals with the concept of the resection and reconnection of the hollow parts of the gastrointestinal tract as one of the cornerstones of visceral surgery. In principle, the healing of quite distinctive anastomoses itself speaks for applied BPC 157 therapy, in particular, as a way in which the therapy of anastomoses can be successfully approached and carried out. Some of the anastomoses implicated were esophagogastric, colocolonic, jejunoileal, and ileoileal anastomoses, along with concomitant disturbances, such as esophagitis, sphincter dysfunction, failed intestinal adaptation, colitis, short bowel syndrome, major vessel occlusion, NO-system, and prostaglandins-system dysfunction, which were accordingly counteracted as well, and, finally, findings concerning other anastomoses healing (i.e., nerve and vessel). Moreover, the healing of fistulas, both external and internal, colocutaneous, gastrocutaneous, esophagocutaneous, duodenocutaneous, vesicovaginal, colovesical, and rectovaginal in rats, perceived as anastomoses made between two different tissues which are normally not connected, may also be indicative. This may be a particular reconnection of the parts of the gastrointestinal tract to re-establish adequate integrity depending on the tissue involved, given that both various intestinal anastomoses and various fistulas (intestinal and skin were accordingly healed simultaneously as the fistulas disappeared) were all healed. Full article
(This article belongs to the Special Issue Naturally Occurring Peptides and Proteins and Related Drugs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop